摘要
丝氨酸蛋白酶抑制剂KazalⅠ型(SPINK1)基因突变的致病机制复杂,众多学者对其在特发性慢性胰腺炎(ICP)中的作用和临床特点进行了深入研究,中日韩在该方面的初步结果与欧美国家有所不同,仍需进一步探讨。
The researches on pancreatic secretory trypsin inhibitor（ PSTI）, also known as the serine protease inhibitor Kazal type 1 （SPINK1）, have led to a new way for the pathogenic mechanism of idiopathic chronic pancreatitis （ICP）. The patients with SPINK1 mutation are thought to have a different clinical features from cases without the mutation, Preliminary results in China, Japan and Korea were different from those in Europe and America.
出处
《国际内科学杂志》
CAS
2008年第3期162-166,共5页
International Journal of Internal Medicine
